GlobeNewswire Inc | Jan 7, 2022 07:00AM EST

January 07, 2022

AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate at two virtual conferences in January.

Event H.C. Wainwright BioConnect ConferenceDate January 10-13, 2022Time Presentation available on demand starting January 10 at 7:00 a.m. ET Event Biotech Showcase 2022Date January 10-12 & 17-19, 2022Time Presentation available on demand

A webcast of the H.C. Wainwright presentation will be available under the Events tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com. A webcast replay will be accessible for 90 days following the event.

Investors interested in arranging a virtual meeting with the Companys management during the Biotech Showcase 2022 conference should contact the conference coordinator. The Companys Biotech Showcase presentation can be accessed on demand to qualified investors through a complimentary registration on the conference website here: Biotech Showcase Registration.

About Plus Therapeutics

Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found atPlusTherapeutics.com and ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as designed to, will, can, potential, focus, preparing, next steps, possibly, and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Companys future performance including the next steps in developing the Companys current assets; the Companys clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Companys platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Companys actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Companys product candidates and therapies, the results of the Companys research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Companys liquidity and capital resources and its ability to raise additional cash, the outcome of the Companys partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading Risk Factors in the Companys Securities and Exchange Commission filings, including in the Companys annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor ContactPeter VozzoICR Westwicke(443) 377-4767Peter.Vozzo@westwicke.com

Media ContactTerri ClevengerICR Westwicke(203) 856-4326Terri.Clevenger@westwicke.com